Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice

Molecular Medicine Reports

Volumn 1, Issue 5, 2008, Pages 657-661

  Nakagami, Hironori ^a   Osako, Mariana Kiomy ^a   Takami, Yoichi ^a   Hanayama, Rie ^a   Koriyama, Hiroshi ^a   Mori, Masaki ^a   Hayashi, Hiroki ^a   Shimizu, Hideo ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein E; Endothelial function; Fatty liver; Hepatocyte growth factor; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; INTERLEUKIN 6; LOSARTAN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCATTER FACTOR; TELMISARTAN; TRIACYLGLYCEROL; VASCULOTROPIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; LIPID DIET; LIPID STORAGE; MOUSE; NONHUMAN; ORGAN WEIGHT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

MUS;

EID: 69449095851     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000008     Document Type: Article

References (25)

1. De Gasparo M, Catt KJ, Inagami T, Wright JW and Unger T: International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472, 2000.
2. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002, 2004.
3. Schupp M, Janke J, Clasen R, Unger T and Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057, 2004. (Pubitemid 38620211)
4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956, 1995.
5. Rosen ED and Spiegelman BM: PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734, 2001. (Pubitemid 37384014)
6. Picard F and Auwerx J: PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22: 167-197, 2002.
7. Nissen SE, Nicholls SJ, Wolski K, et al: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299: 1561-1573, 2008.
8. Schupp M, Clemenz M, Gineste R, et al: Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452, 2005. (Pubitemid 43334334)
9. Hayashi K, Nakamura S, Morishita R, et al: In vivo transfer of human hepatocyte growth factor gene accelerates reendothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 7: 1664-1671, 2000.
10. Takaya T, Kawashima S, Shinohara M, et al: Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 186: 402-410, 2006.
11. Uruno A, Sugawara A, Kanatsuka H, et al: Hepatocyte growth factor stimulates nitric oxide production through endothelial nitric oxide synthase activation by the phosphoinositide 3-kinase/Akt pathway and possibly by mitogen-activated protein kinase kinase in vascular endothelial cells. Hypertens Res 27: 887-895, 2004. (Pubitemid 40309455)
12. Makondo K, Kimura K, Kitamura N, et al: Hepatocyte growth factor activates endothelial nitric oxide synthase by Ca(2+)- and phosphoinositide 3-kinase/Akt-dependent phosphorylation in aortic endothelial cells. Biochem J 374: 63-69, 2003. (Pubitemid 37046929)
13. Nakagami H, Morishita R, Yamamoto K, et al: Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. Diabetes 51: 2604-2611, 2002. (Pubitemid 34827413)
14. Taniyama Y, Morishita R, Aoki M, et al: Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 8: 181-189, 2001. (Pubitemid 32186129)
15. Nakamura S, Morishita R, Moriguchi A, et al: Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens 16: 2019-2026, 1998. (Pubitemid 29002383)
16. Morishita R, Nakamura S, Nakamura Y, et al: Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 46: 138-142, 1997. (Pubitemid 27009962)
17. Hayashi S, Morishita R, Nakamura S, et al: Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 100: II301-II308, 1999. (Pubitemid 29523551)
18. Taniyama Y, Morishita R, Nakagami H, et al: Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102: 246-252, 2000. (Pubitemid 30451784)
19. Nakano N, Moriguchi A, Morishita R, et al: Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. Hypertension 30: 1448-1454, 1997. (Pubitemid 27528088)
20. Nakano N, Morishita R, Moriguchi A, et al: Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. Hypertension 32: 444-451, 1998. (Pubitemid 28429132)
21. Li Y, Wen X, Spataro BC, Hu K, Dai C and Liu Y: Hepatocyte growth factor is a downstream effector that mediates the anti-fibrotic action of peroxisome proliferator-activated receptorgamma agonists. J Am Soc Nephrol 17: 54-65, 2006.
22. Angulo P: Nonalcoholic fatty liver disease. N Eng J Med 346: 1221-1231, 2002.
23. Angulo P: Obesity and nonalcoholic fatty liver disease. Nutr Rev 65: S57-S63, 2007.
24. Fujita K, Yoneda M, Wada K, et al: Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 52: 3455-3464, 2007. (Pubitemid 350077187)
25. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T and Kurtz TW: Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-1009, 2006. (Pubitemid 44297575)